Kodiak Sciences (NASDAQ:KOD) Stock Price Expected to Rise, UBS Group Analyst Says

Kodiak Sciences (NASDAQ:KOD) had its target price boosted by UBS Group from $50.00 to $80.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s price target would suggest a potential upside of 116.22% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of Kodiak Sciences in a report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $58.00 target price (up from $38.00) on shares of Kodiak Sciences in a report on Friday. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $35.43.

Kodiak Sciences Stock Performance

KOD stock opened at $37.00 on Friday. The stock’s 50 day simple moving average is $25.14 and its 200 day simple moving average is $21.89. The company has a market cap of $1.96 billion, a P/E ratio of -8.98 and a beta of 2.61. Kodiak Sciences has a fifty-two week low of $1.92 and a fifty-two week high of $45.60.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC grew its position in Kodiak Sciences by 1,221.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock worth $28,000 after purchasing an additional 916 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Kodiak Sciences in the 4th quarter valued at about $29,000. Cerity Partners LLC lifted its position in shares of Kodiak Sciences by 7.4% during the 4th quarter. Cerity Partners LLC now owns 16,446 shares of the company’s stock worth $460,000 after buying an additional 1,139 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Kodiak Sciences during the 4th quarter worth approximately $72,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of Kodiak Sciences by 89.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,373 shares of the company’s stock worth $104,000 after buying an additional 3,009 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

Trending Headlines about Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Topline Phase 3 (GLOW2) win for Zenkuda: Kodiak reported that Zenkuda (tarcocimab tedromer) met the primary endpoint in GLOW2, showing a large improvement in diabetic retinopathy severity (62.5% of treated patients achieved ≥2‑step DRSS improvement vs 3.3% for sham) with a 6‑month dosing interval — a result that materially raises the drug’s efficacy and commercial prospects. PR Newswire
• Positive Sentiment: Market reaction: The GLOW2 news triggered large intraday rallies (reports of 50–75%+ moves) as traders repriced KOD for a potential regulatory filing and eventual launch. This surge reflected investor expectations that the program can support a Biologics License Application (BLA) and a valuable ophthalmology franchise. Reuters
• Positive Sentiment: Analyst upgrades and higher price targets: Following the data, UBS raised its price target to $80 with a Buy rating and HC Wainwright reaffirmed Buy while raising its target to $58 — both moves signal increased sell‑side conviction and provide further upside narrative for investors. Benzinga (UBS) TickerReport (HC Wainwright)
• Neutral Sentiment: Regulatory path and next steps: Coverage notes and industry press indicate a likely BLA filing is now the logical next step; timing and FDA interactions remain catalysts but are not guaranteed. Positive data increase probability, but approval and commercial uptake timelines still carry execution risk. BioWorld
• Negative Sentiment: Volatility and hedging activity: There was unusually high put option activity the day of the results (large put volumes vs typical), indicating some traders were hedging or positioning for downside — a sign of elevated speculative interest and potential for sharp intraday reversals. (Options flow reported 3,472 puts vs typical ~256.)
• Negative Sentiment: Today’s pullback amid heavy volume: After the strong rally on the data, the shares have pulled back today on very heavy trading — a common post‑news profit taking and volatility washout that increases short‑term risk despite the fundamentally positive trial news.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.